Evidence map›Paper›PMID 40452887›Full record

ReviewExploration of targeted anti-tumor therapy2025

Circulating tumor cells: overcoming challenges of detecting a needle in a haystack.

Zhuldyz Myrkhiyeva, Kuanysh Seitkamal, Zhannat Ashikbayeva, Assiya Taizhanova, Daniele Tosi, Aliya Bekmurzayeva

Abstract readReview
In one paragraph

Review in Exploration of targeted anti-tumor therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhuldyz MyrkhiyevaLaboratory of Biosensors and Bioinstruments, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID https://orcid.org/0000-0001-8644-2528
Kuanysh SeitkamalLaboratory of Biosensors and Bioinstruments, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID https://orcid.org/0000-0002-6242-447X
Zhannat AshikbayevaLaboratory of Biosensors and Bioinstruments, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID https://orcid.org/0000-0001-9057-5876
Assiya TaizhanovaLaboratory of Biosensors and Bioinstruments, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID https://orcid.org/0009-0007-9822-9581
Daniele TosiLaboratory of Biosensors and Bioinstruments, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID https://orcid.org/0000-0002-6500-4964
Aliya BekmurzayevaLaboratory of Biosensors and Bioinstruments, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Astana 010000, Kazakhstan.ORCID https://orcid.org/0000-0002-2780-1006

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating tumor cells (CTCs) are cancer cells that are detached from the primary and metastatic tumor site and invade the bloodstream. Most importantly, CTCs are the key players in the development of metastasis. As one of the main components of liquid biopsy, they may significantly contribute to improvements in early cancer diagnosis, monitoring response to therapy, and predicting recurrence of the disease. Although identifying and analyzing CTCs offers the potential for a real-time liquid biopsy, their detection is associated with a number of challenges, which mainly stem from three sources: complexity of the CTCs, complexity of the media (blood), and performance of the detection assays. Particularly, low concentration of the CTCs and the presence of a vast population of hematopoietic cells in the blood make their detection technically complex. The heterogeneity of the target cells and not enough sensitivity of the measuring platforms are also among major technical challenges in CTC detection. Therefore, this review aims to give an update on various methods developed for CTC isolation, including chip-based assays and biosensors. The work will elucidate various challenges associated with the isolation and detection of CTCs and showcase the studies that aimed to tackle them. A number of available commercial platforms for CTC detection and hurdles associated with their widespread applications in clinical settings will also be discussed.

Indexed as

biosensorcancerCirculating tumor cellscommercial assaysdetectionliquid biopsy

Identifiers

PMID40452887
PMCPMC12123222

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.